IDT expands commercial scale pharmaceutical manufacturing
31 Jul, 2021 | Newsletters
|IDT Australia*,(Institute of Drug Technology Limited) recently installed their new Avestin EmulsiFlex C55. With a flow rate of up to 55L/hr, this system bridges the gap between a benchtop and production scale high pressure homogeniser that can be applied to cell disruption (Bacteria, Yeast, Algae, Insect and Mammalian cells), liposomal products, emulsions and particle size reduction.
A unique “dynamic” homogenising valve and no “O”-rings or gaskets in the entire path of the product, means less risk for contamination or blockage. The C55 is versatile in terms of suitable sample sizes, processing a minimum sample volume of only 100mL and allowing for adjustable flow rates down to ~18L/hr and temperature control. The system is suitable for GMP compliance as well as compliance to 21 CFR Part 11.
*IDT is an Australian cGMP pharmaceutical manufacturing company that specialises in high containment, high potency manufacture of Active Pharmaceutical Ingredients (API) and Finished Dose Forms (FDF), as well as offering a full suite of contract manufacturing services.
For more information on the Avestin range and accessories, please contact us below:
Contact us for more information
Other popular high pressure homogenisers used to efficiently reduce particles and droplets from micron to nanometer sizes include:
Avestin Emulsiflex C5 is a lab scale, air driven, high pressure homogeniser.
Avestin Emulsiflex C3 is a lab scale, electric motor driven, high pressure homogeniser.
|Request a call back
Request sample testing
Request service or support